University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > David M. Jablons

David M. Jablons, M.D.

Chief of Thoracic Surgery

Dr. David M. Jablons is a renowned lung cancer expert, chief of General Thoracic Surgery at UCSF Medical Center and program leader of the Thoracic Oncology Program of the UCSF Helen Diller Family Comprehensive Cancer Center. He also is director of the UCSF Thoracic Oncology Laboratory where he is investigating molecular biology and genomics.

Jablons earned an undergraduate degree from Yale University and a medical degree from Albany Medical College of Union University. He completed a surgical residency at Tufts-New England Medical Center. He has written numerous research papers and frequently lectures about lung cancer at international and national meetings. He is a member of many professional organizations, including the American Association for Cancer Research, International Association for the Study of Lung Cancer, Society of Thoracic Surgeons and the American Association for the Advancement of Science.

Clinics

Thoracic Surgery and Oncology
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 885-3882
Fax: (415) 353-9525

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about David M. Jablons

Additional Languages

Chinese
French
Russian
Spanish

Education

Albany Medical College 1984

Residencies

Tufts-New England Medical Center, General Surgery 1991

Fellowships

New York Hospital-Cornell University, Cardiothoracic Surgery 1993

Selected Research and Publications

  1. Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun. 2013 Apr 16; 4:1701.
  2. Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B. Gli as a novel therapeutic target in malignant pleural mesothelioma. PLoS One. 2013; 8(3):e57346.
  3. Mann MJ, Jablons DM, Kratz JR. Prognostic assay in small, node-negative non-small cell lung cancer--reply. JAMA. 2013 Feb 27; 309(8):769-70.
  4. Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N. SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J Exp Clin Cancer Res. 2013; 32:7.
  5. Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study. BMJ Open. 2012; 2(6).
  6. Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B. The role of stem cells in airway repair: implications for the origins of lung cancer. Chin J Cancer. 2013 Feb; 32(2):71-4.
  7. Kratz JR, Van den Eeden SK, He J, Jablons DM, Mann MJ. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA. 2012 Oct 24; 308(16):1629-31.
  8. Mulvihill MS, Kwon YW, Lee S, Fang LT, Choi H, Ray R, Kang HC, Mao JH, Jablons D, Kim IJ. Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. PLoS One. 2012; 7(8):e42264.
  9. Kim JW, Lee S, Lui N, Choi H, Mulvihill M, Fang LT, Kang HC, Kwon YW, Jablons D, Kim IJ. A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. Oncol Rep. 2012 Oct; 28(4):1225-30.
  10. Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012; 7(6):e38996.
  11. Li T, Hou SC, Mao JH, Wang YC, Lu XD, Tan JL, You B, Liu YP, Ni J, Au A, Jablons DM, Xu Z, You L. The expression of Dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma. J Clin Pathol. 2012 Sep; 65(9):855-8.
  12. Yom SS, Chen CP, Jahan TM, Jablons DM. One size does not fit all lung cancer patients. J Thorac Oncol. 2012 May; 7(5):945.
  13. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 3; 379(9818):823-32.
  14. Chen CP, Weinberg VK, Jahan TM, Jablons DM, Yom SS. Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. J Thorac Oncol. 2011 Nov; 6(11):1857-64.
  15. Markovics JA, Araya J, Cambier S, Somanath S, Gline S, Jablons D, Hill A, Wolters PJ, Nishimura SL. Interleukin-1beta induces increased transcriptional activation of the transforming growth factor-beta-activating integrin subunit beta8 through altering chromatin architecture. J Biol Chem. 2011 Oct 21; 286(42):36864-74.
  16. Schmid S, Bieber M, Zhang F, Zhang M, He B, Jablons D, Teng NN. Wnt and hedgehog gene pathway expression in serous ovarian cancer. Int J Gynecol Cancer. 2011 Aug; 21(6):975-80.
  17. Barbone D, Ryan JA, Kolhatkar N, Chacko AD, Jablons DM, Sugarbaker DJ, Bueno R, Letai AG, Coussens LM, Fennell DA, Broaddus VC. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis. 2011; 2:e174.
  18. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin avß8-mediated activation of TGF-ß. J Clin Invest. 2011 Jul; 121(7):2863-75.
  19. Okamoto J, Kratz JR, Hirata T, Mikami I, Raz D, Segal M, Chen Z, Zhou HM, Pham P, Li H, Yagui-Beltran A, Beltran A, Ray MR, Koizumi K, Shimizu K, Jablons D, He B. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients. Clin Lung Cancer. 2011 Jul; 12(4):237-44.
  20. Li T, Hung MS, Wang Y, Mao JH, Tan JL, Jahan K, Roos H, Xu Z, Jablons DM, You L. Transgenic mice for cre-inducible overexpression of the Cul4A gene. Genesis. 2011 Mar; 49(3):134-41.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California